Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Zonegran

- PMLiVE

Eisai adds online patient stories to Belviq marketing

Belviq Voices 'online community' will featureweight loss patient experiences

EISAI

Eisai given early approval for new oncology drug

Japanese firm’s thyroid cancer treatment Lenvimaset to be a blockbuster

- PMLiVE

UCB submits brivaracetam for use in epilepsy

Files drug in both the US and EU

- PMLiVE

UCB partners with Daiichi to bring epilepsy drug to Japan

Companies partner on expanding market for Vimpat

EISAI

Eisai establishes neuroscience unit in Belgium and Luxembourg

Follows the company's recent expansion in Australia

- PMLiVE

Eisai’s cancer cookbook wins CSR award

Around the Kitchen Table project see success at PMEA 2014

EISAI

Eisai opens first office in Australia

New Melbourne base to support marketing of Halaven and Fycompa

EISAI

Eisai “speechless” as G-BA denies price premium for Fycompa

But company has better news on cancer drug Halaven

- PMLiVE

Eisai backs competition to find star of epilepsy comic book

Teams up with Medikidz to educate young people about the condition

- PMLiVE

Eisai launches online breast cancer resource

Website includes information on the disease, treatment options and side effects

- PMLiVE

Eisai wins US approval for chemotherapy side effects drug

FDA backs Akynzeo to treat nausea and vomiting

- PMLiVE

UCB wins new epilepsy indication for Vimpat in the US

FDA approves drug as monotherapy in patients with partial-onset seizures

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links